The CAR-NK strategies that have progressed the furthest in solid tumors target the checkpoint molecule programmed cell death protein-1 ligand (PD-L1), as well as common tumor-associated antigens HER2 and mucin1 (MUC1). The gene discussed is CD274; the disease is neoplasm.